Tenders Are Invited For Pharmaceutical Products – Medicines With The Active Ingredient Infliximab (Atc: L04a ... in Germany

Work Detail

Pharmaceutical Products – Medicines With The Active Ingredient Infliximab (Atc: L04ab02). Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For Finished Medicinal Products With The Active Ingredient Infliximab (Atc: L04ab02) With The Possibility Of Conclusion At Any Time As Part Of A So-Called Open-House Model. A Contract Is Concluded With Each Pharmaceutical Company That Meets The Participation Requirements. There Is No Exclusivity. Joining Or Concluding A Contract Can Take Place At Any Time And Under The Same Conditions. Individual Contract Negotiations Will Not Be Carried Out. The Earliest Start Of The Contract Is July 1St, 2026. Based On This, The Contract Term Is A Maximum Of 24 Months. The Contract Ends On June 30, 2028 Regardless Of The Start Of The Contract. Should Aok Sachsen-Anhalt Tender Exclusive Contracts For The Active Ingredients During The Contract Term In Accordance With The Relevant Procurement Regulations, The Contracts Concluded Within The Framework Of This Publication Will Be Terminated In Accordance With The Contractual Provisions. This Publication Does Not Involve The Award Of A Public Contract Within The Meaning Of Section 103 Gwb Or Public Procurement Law. In Order To Ensure The Greatest Possible Degree Of Transparency For The Intended Conclusion Of Contracts, Publication Will Take Place In The Supplement To The Official Journal Of The European Union. In The Absence Of A Corresponding Publication Form, The Contract Notice Will Be Used. The Resulting Conceptual Specifications, Such As The Procedural Designation Open Procedure, Are Solely Due To The Use Of This Announcement Form And The Publication Platform. This Does Not Entail Any Further Meaning, In Particular Subjection To Procurement Regulations, Unless They Are Binding For Legal Reasons.

Contact Information